Navigation Links
Genaera Corporation's 2008 Annual Stockholder Meeting Results
Date:5/30/2008

PLYMOUTH MEETING, Pa., May 30 /PRNewswire-FirstCall/ -- Genaera Corporation (Nasdaq: GENR) today announced the results of its Annual Meeting of Stockholders held on May 29, 2008. Proxies representing a majority of the shares voted at the Annual Meeting were cast in favor of the resolutions brought before the stockholders.

As a result, at the meeting:

-- John L. Armstrong, Jr., R. Frank Ecock, Zola P. Horovitz, Ph.D.,

Mitchell D. Kaye, Osagie O. Imasogie and Robert F. Shapiro were all

re-elected to the Company's Board of Directors;

-- Genaera's 2004 Stock-Based Incentive Compensation Plan was amended to

provide for an increased number of shares issuable thereunder; and

-- KPMG LLP was appointed as the Company's independent registered public

accounting firm for the fiscal year ending December 31, 2008.

About Genaera

Genaera Corporation is focused on advancing the science and treatment of metabolic diseases. The Company has significant market opportunities with a first-in-class molecule, trodusquemine (MSI-1436), that has the potential to redefine the treatment paradigm for obesity and type 2 diabetes and is presently in a phase 1 trial in obesity. In addition, Genaera has a value-driven, fully out-licensed partnership with MedImmune, Inc. for a second core program that is presently undergoing phase 2 clinical testing in asthma. Genaera is committed to directing resources to its core program and the aggressive clinical development of its key assets to build stockholder value. For further information, please see our website at http://www.genaera.com.

This announcement contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties, known and unknown. Forward-looking statements reflect management's current views and are based on certain expectations and assumptions. Such statements include, among others, statements regarding the preliminary results, clinical development plans and prospects for Genaera's programs including trodusquemine (MSI-1436) and the IL-9 antibody program. You may identify some of these forward-looking statements by the use of words in the statements such as "anticipate," "believe," "continue," "develop," "expect," "plan" and "potential" or other words of similar meaning. Genaera's actual results and performance could differ materially from those currently anticipated and expressed in these and other forward-looking statements as a result of a number of risk factors, including, but not limited to: Genaera's history of operating losses since inception and its need for additional funds to operate its business; the costs, delays and uncertainties inherent in scientific research, drug development, clinical trials and the regulatory approval process; the risk that clinical trials for Genaera's product candidates including trodusquemine (MSI-1436) and the IL-9 antibody program may be delayed or may not be successful; the risk that Genaera may not obtain regulatory approval for its products, whether due to adequacy of the development program, the conduct of the clinical trials, changing regulatory requirements, different methods of evaluating and interpreting data, regulatory interpretations of clinical risk and benefit, or otherwise; Genaera's reliance on its collaborators, in connection with the development and commercialization of Genaera's product candidates; market acceptance of Genaera's products, if regulatory approval is achieved; competition; general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industry; and the other risks and uncertainties discussed in this announcement and in Genaera's filings with the U.S. Securities and Exchange Commission, all of which are available from the Commission in its EDGAR database at http://www.sec.gov as well as other sources. You are encouraged to read these reports. Given the uncertainties affecting development stage pharmaceutical companies, you are cautioned not to place undue reliance on any such forward-looking statements, any of which may turn out to be wrong due to inaccurate assumptions, unknown risks, uncertainties or other factors. Genaera does not intend (and it is not obligated) to publicly update, revise or correct these forward-looking statements or the risk factors that may relate thereto.


'/>"/>
SOURCE Genaera Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Xmark Comments on Genaera Cost-Saving Plan
2. Genaera Corporation Receives Audit Opinion Containing Going Concern Explanatory Paragraph
3. Genaera Corporation Announces Licensing of Exclusive Rights to Pexiganan, a Novel Anti-Infective Drug Candidate, by Macrochem Corporation
4. Genaera Announces Formation of Scientific Advisory Board for Obesity Drug Candidate Trodusquemine (MSI-1436)
5. Nationally Recognized Corporations and Retailers Rally Behind breastcancer.org
6. Rivaroxaban phase III pivotal data presented at EFORT annual meeting
7. NYP/Columbia physician-scientists present at ASCO 44th annual meeting
8. AMERIGROUP Corporation to Present at the Goldman Sachs 29th Annual Global Healthcare Conference on June 11
9. China Nepstar Chain Drugstore Filed Its Annual Report on Form 20-F
10. Alseres Pharmaceuticals, Inc. Announces 2008 Annual Stockholders Meeting
11. Longs Drug Stores Corporation Announced at Its Annual Meeting of Stockholders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... ROSEMONT, IL (PRWEB) , ... ... ... Research and Education Foundation (OREF), in partnership with the American Society of ... Patient Safety Foundation (APSF), the American Academy of Orthopaedic Surgeons (AAOS) and ...
(Date:1/23/2017)... ... 23, 2017 , ... “Crossing the Bar”: a moving and eloquent drama ... “Crossing the Bar” is the creation of published author, Charlotte Hotte, a North Carolina ... credits the inspiration of the book to her sister, Denise, wishes to acknowledge her ...
(Date:1/23/2017)... ... January 23, 2017 , ... “Some Infallible Characteristics of Christ”: a ... Characteristics of Christ” is the creation of published author, Rev. Dr. Robert W. Thomas, ... thirteen years, a preacher for over nineteen, a pastor for over fifteen years. He ...
(Date:1/22/2017)... ... 22, 2017 , ... Zifam Pinnacle, an Australian company dedicated to providing a ... retail buyers at the January ECRM Trade Show in Hilton Head, SC. , Zifam ... standards in all of its creations to help create a more traditional and natural ...
(Date:1/21/2017)... , ... January 21, 2017 , ... Caronlab Australia, an ... the January ECRM Trade Show in Hilton Head, SC, where it benefited from outstanding ... the quality of its beauty and wellness products. At this trade show, the company ...
Breaking Medicine News(10 mins):
(Date:1/23/2017)... 23, 2017 7D Surgical announced today ... the U.S. Food and Drug Administration (FDA) and ... the North American commercial launch of its innovative ... surgery, the 7D Surgical System.  ... technologies and machine vision algorithms to eliminate the ...
(Date:1/23/2017)... Research and Markets has announced the addition of the "Needle ... 2025" report to their offering. ... Report Highlights: The report provides a ... opportunities Market forecasts till 2025, using estimated market values ... business segments, Regions and Countries Key developments and strategies ...
(Date:1/23/2017)... , January 23, 2017 ... riñón (r enal) y el ... dosis de a pabetalone    Resverlogix ... los resultados preliminares de un ensayo en fase 1 ... discapacidad de riñón (renal) severa. Los datos demostraron unos ...
Breaking Medicine Technology: